Rindopepimut

Summary

Rindopepimut (CHEMBL2107863) is a phase-3 clinical-stage unknown; indicated across 3 conditions including gliosarcoma and glioblastoma; with CIViC clinical evidence for 1 variant-indication association (e.g. EGFR VIII in glioblastoma).

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 3 conditions
• Clinical trials: 4
• Precision-oncology evidence (CIViC): 1 variant–indication association

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107863
Name	Rindopepimut
Type	Unknown
Max phase	3

Also known as: CDX-110, PF-04948568, PF-04948568 (FORMERLY CDX-110), Rindopepimut, RINDOPEPIMUT

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gliosarcoma	3	MONDO:0016681	EFO:1001465
glioblastoma	3	MONDO:0018177	EFO:0000519
glioma	2	MONDO:0021042	MONDO:0100342

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01480479	PHASE3	COMPLETED	Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
NCT01498328	PHASE2	COMPLETED	A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
NCT01058850	PHASE1	TERMINATED	Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas
NCT03068650	Not specified	NO_LONGER_AVAILABLE	Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
EGFR VIII	Glioblastoma	Sensitivity/Response	Rindopepimut	CIViC B	EID971

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).